Diffusion of interleukin-2 from cells overlaid with cytocompatible enzyme-crosslinked gelatin hydrogels

Journal of Biomedical Materials Research - Part A

Volumn 95, Issue 1, 2010, Pages 25-32

  Yung, Chong Wing ^a,b   Bentley, William E ^a,b   Barbari, Timothy A ^a  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE   (United States)

Author keywords

Continuous drug delivery; Crosslinked gelatin hydrogel; Diffusion coefficient; Human interleukin 2; Microbial transglutaminase

Indexed keywords

CONTINUOUS DRUG DELIVERY; CROSSLINKED; DIFFUSION COEFFICIENT; HUMAN INTERLEUKIN; MICROBIAL TRANSGLUTAMINASE;

BIOLOGICAL MATERIALS; DIFFUSION; DRUG DELIVERY; DRUG PRODUCTS; GELS; GENETIC ENGINEERING; PROTEINS; TRANSPORT PROPERTIES;

HYDROGELS;

GELATIN; HUMAN INTERLEUKIN 2; INTERLEUKIN 2; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; UNCLASSIFIED DRUG;

ARTICLE; BIOCOMPATIBILITY; CELL ENCAPSULATION; CELL MEMBRANE; CELL STRAIN HEK293; CYTOKINE PRODUCTION; DIFFUSION CHAMBER; DIFFUSION COEFFICIENT; DRUG DIFFUSION; DRUG ELIMINATION; EMBRYO; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC ENGINEERING; HUMAN; HUMAN CELL; HYDROGEL; INTERNAL RIBOSOME ENTRY SITE; MATHEMATICAL MODEL; MICROENVIRONMENT; MODEL; PROTEIN CROSS LINKING; PROTEIN SECRETION; PROTEIN SYNTHESIS; STEADY STATE; SUSTAINED DRUG RELEASE; CYTOKINE RELEASE; IMMUNODIFFUSION;

BIOCOMPATIBLE MATERIALS; CROSS-LINKING REAGENTS; DIFFUSION; FLUORESCENCE; GELATIN; HEK293 CELLS; HUMANS; HYDROGELS; INTERLEUKIN-2; LINEAR MODELS; LUMINESCENT PROTEINS; MODELS, BIOLOGICAL; TIME FACTORS; TRANSGLUTAMINASES;

EID: 77956486047     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.32740     Document Type: Article

References (35)

1. Lee KY, Mooney DJ. Hydrogels for tissue engineering. Chem Rev 2001;101:1869-1879.
2. Drury JL, Mooney DJ. Hydrogels for tissue engineering: Scaffold design variables and applications. Biomaterials 2003;24:4337-4351.
3. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Molecular Biology of the Cell. 4th ed. New York: Garland Science; 2002.
4. Mammoto A, Connor KM, Mammoto T, Yung CW, Huh D, Aderman CM, Mostoslavsky G, Smith LE, Ingber DE. A mechanosensitive transcriptional mechanism that controls angiogenesis. Nature 2009;457:1103-1108.
5. Choi YS, Hong SR, Lee YM, Song KW, Park MH, Nam YS. Studies on gelatin-containing artificial skin. II. Preparation and characterization of cross-linked gelatin-hyaluronate sponge. J Biomed Mater Res 1999;48:631-639.
6. Choi YS, Hong SR, Lee YM, Song KW, Park MH, Nam YS. Study on gelatin-containing artificial skin. I. Preparation and characteristics of novel gelatin-alginate sponge. Biomaterials 1999;20:409-417.
7. Elisseeff J, Anseth K, Sims D, McIntosh W, Randolph M, Yaremchuk M, Langer R. Transdermal photopolymerization of poly(ethylene oxide)-based injectable hydrogels for tissue-engineered cartilage. Plast Reconstr Surg 1999;104:1014-1022.
8. Barker H, Oliver R, Grant R, Stephen L. Formaldehyde as a pretreatment for dermal collagen heterografts. Biochim Biophys Acta 1980;632:589-597. (Pubitemid 11203306)
9. Gendler E, Gendler S, Nimni ME. Toxic reactions evoked by glutaraldehyde-fixed pericardium and cardiac valve tissue bioprosthesis. J Biomed Mater Res 1984;18:727-736. (Pubitemid 14013473)
10. Williams CG, Malik AN, Kim TK, Manson PN, Elisseeff JH. Variable cytocompatibility of six cell lines with photoinitiators used for polymerizing hydrogels and cell encapsulation. Biomaterials 2005;26:1211-1218.
11. Yokoyama K, Nio N, Kikuchi Y. Properties and applications of microbial transglutaminase. Appl Microbiol Biotechnol 2004;64:447-454.
12. Yokoyama K, Kikuchi Y, Yasueda H. Overproduction of DnaJ in Escherichia coli improves in vivo solubility of the recombinant fish-derived transglutaminase. Biosci Biotechnol Biochem 1998;62:1205-1210.
13. Chen T, Embree HD, Brown EM, Taylor MM, Payne GF. Enzymecatalyzed gel formation of gelatin and chitosan: Potential for in situ applications. Biomaterials 2003;24:2831-2841.
14. Chen T, Small DA, McDermott MK, Bentley WE, Payne GF. Enzymatic methods for in situ cell entrapment and cell release. Biomacromolecules 2003;4:1558-1563. (Pubitemid 37455566)
15. Kobayashi K, Hashiguchi K, Yokozeki K, Yamanaka S. Molecular cloning of the transglutaminase gene from Bacillus subtilis and its expression in Escherichia coli. Biosci Biotechnol Biochem 1998;62:1109-1114.
16. Hong SR, Lee SJ, Shim JW, Choi YS, Lee YM, Song KW, Park MH, Nam YS, Lee SI. Study on gelatin-containing artificial skin IV: A comparative study on the effect of antibiotic and EGF on cell proliferation during epidermal healing. Biomaterials 2001;22:2777-2783.
17. Paguirigan AL, Beebe DJ. Protocol for the fabrication of enzymatically crosslinked gelatin microchannels for microfluidic cell culture. Nat Protoc 2007;2:1782-1788.
18. Paguirigan A, Beebe DJ. Gelatin based microfluidic devices for cell culture. Lab Chip 2006;6:407-413.
19. Yung CW, Wu LQ, Tullman JA, Payne GF, Bentley WE, Barbari TA. Transglutaminase crosslinked gelatin as a tissue engineering scaffold. J Biomed Mater Res A 2007;83:1039-1046. (Pubitemid 350231764)
20. Otter WD, Cadee J, Gavhumende R, De Groot CJ, Hennink WE, Stewart R. Effective cancer therapy with a single injection of interleukin- 2 at the site of the tumour. Cancer Immunol Immunother 1999;48:419-420.
21. Dejaco C, Duftner C, Schirmer M. Induction of tolerance in autoimmune diseases rather than cure of cancer by interleukin-2 therapy. J Clin Oncol 2006;24:e34; author reply e35-e36.
22. Recchia F, De Filippis S, Rosselli M, Saggio G, Cesta A, Fumagalli L, Rea S. Phase 1B study of subcutaneously administered interleukin 2 in combination with 13-cis retinoic acid as maintenance therapy in advanced cancer. Clin Cancer Res 2001;7:1251-1257.
23. Recchia F, Saggio G, Cesta A, Alesse E, Gallo R, Necozione S, Rea S. Phase II randomized study of interleukin-2 with or without 13-cis retinoic acid as maintenance therapy in patients with advanced cancer responsive to chemotherapy. Anticancer Res 2005;25:3149-3157.
24. Farag SS, George SL, Lee EJ, Baer M, Dodge RK, Becknell B, Fehniger TA, Silverman LR, Crawford J, Bloomfield CD, Larson RA, Schiffer CA, Caligiuri MA. Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and leukemia group B study 9420. Clin Cancer Res 2002;8:2812-2819. (Pubitemid 35025724)
25. Yung CW, Barbari TA, Bentley WE. Integrated non-invasive system for quantifying secreted human therapeutic hIL2. Biotechnol Bioeng 2006;95:938-945.
26. Yung CW, Barbari TA, Bentley WE. Counteracting apoptosis and necrosis with hypoxia responsive expression of Bcl-2Delta. Metab Eng 2006;8:483-490.
27. Truskey GA, Yuan F, Katz DF. Transport Phenomena in Biological Systems. Upper Saddle River, New Jersey: Prentice Hall; 2004. p 816.
28. Oktem O, Oktay K. The role of extracellular matrix and activin-A in in vitro growth and survival of murine preantral follicles. Reprod Sci 2007;14:358-366. (Pubitemid 351168809)
29. Ingber DE, Folkman J. Mechanochemical switching between growth and differentiation during fibroblast growth factor-stimulated angiogenesis in vitro: Role of extracellular matrix. J Cell Biol 1989;109:317-330. (Pubitemid 19180139)
30. Figueroa B Jr, Sauerwald TM, Oyler GA, Hardwick JM, Betenbaugh MJ. A comparison of the properties of a Bcl-xL variant to the wild-type anti-apoptosis inhibitor in mammalian cell cultures. Metab Eng 2003;5:230-245.
31. Figueroa B Jr, Sauerwald TM, Mastrangelo AJ, Hardwick JM, Betenbaugh MJ. Comparison of Bcl-2 to a Bcl-2 deletion mutant for mammalian cells exposed to culture insults. Biotechnol Bioeng 2001;73:211-222.
32. Mastrangelo AJ, Hardwick JM, Bex F, Betenbaugh MJ. I. Bcl-2 and Bcl-x(L) limit apoptosis upon infection with alphavirus vectors. Biotechnol Bioeng 2000;67:544-554.
33. Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990;50(3 Suppl):814s-819s.
34. Shaw J, Monticone V, Paetkau V. Partial purification and molecular characterization of a lymphokine (costimulator) required for the mitogenic response of mouse thymocytes in vitro. J Immunol 1978;120:1967-1973. (Pubitemid 8356942)
35. Buck KK, Gerhardt NI, Dungan SR, Phillips RJ. The effect of solute concentration on equilibrium partitioning in polymeric gels. J Colloid Interface Sci 2001;234:400-409.